MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Alentis Therapeutics

Alentis Appoints Mark Pruzanski as CEO
From Alentis Therapeutics
Via Business Wire
Alentis Announces Positive Topline Results from Two Studies of Lixudebart (ALE.F02) in Patients with ANCA-RPGN and Advanced Liver Fibrosis
From Alentis Therapeutics
Via Business Wire
Alentis Receives FDA Fast Track Designation for ALE.P02 for the Treatment of CLDN1+ Squamous Solid Tumors
From Alentis Therapeutics
Via Business Wire
Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors
From Alentis Therapeutics
Via Business Wire
Alentis Therapeutics Receives FDA IND Clearance for ALE.P02, a Novel CLDN1-ADC for the Treatment of Squamous Cancers
From Alentis Therapeutics
Via Business Wire
Alentis Appoints Jonathan Freve CFO
From Alentis Therapeutics
Via Business Wire
Alentis Receives FDA Orphan Drug Designation for Lixudebart to Treat Idiopathic Pulmonary Fibrosis
From Alentis Therapeutics
Via Business Wire
Alentis Appoints Alberto Toso Chief Scientific Officer
From Alentis Therapeutics
Via Business Wire
William Pao Joins Alentis Therapeutics as Independent Board Member
From Alentis Therapeutics
Via Business Wire
Alentis Therapeutics Expands Leadership Team with the Appointment of Rizwan Velji as Chief Business Officer
From Alentis Therapeutics
Via Business Wire
Alentis Therapeutics Doses First ANCA-Associated Vasculitis Rapidly Progressive Glomerulonephritis Patient in Phase 2 Clinical Trial of Lixudebart (ALE.F02)
From Alentis Therapeutics
Via Business Wire
Alentis Therapeutics Doses First Patient in Phase 1/2 Clinical Trial of ALE.C04 in Head and Neck Squamous Cell Carcinoma (HNSCC)
From Alentis Therapeutics
Via Business Wire
Alentis Therapeutics Appoints Lung Experts Professors Tony Mok and Steven Nathan to its Scientific Advisory Board
From Alentis Therapeutics
Via Business Wire
Alentis Therapeutics to Present at the European Respiratory Society (ERS) International Congress
From Alentis Therapeutics
Via Business Wire
Alentis Therapeutics Receives FDA Fast Track Designation for ALE.C04 for the Treatment of Claudin-1 Positive HNSCC
From Alentis Therapeutics
Via Business Wire
Alentis Therapeutics Appoints Luca Santarelli as Chairperson
From Alentis Therapeutics
Via Business Wire
Alentis Therapeutics Appoints Prof. David Jayne and Prof. Josep Tabernero to its Scientific Advisory Board
From Alentis Therapeutics
Via Business Wire
Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
From Alentis Therapeutics
Via Business Wire
Alentis Therapeutics Reports Positive Topline Results From Phase 1 Multiple-ascending Dose Cohorts Study
From Alentis Therapeutics
Via Business Wire
Alentis Therapeutics Closes $105 Million Series C Funding to Advance Transformational Medicines for Claudin-1
From Alentis Therapeutics
Via Business Wire
Positive Results from Single Ascending Dose Phase 1 Study of ALE.F02 Targeting Claudin-1
From Alentis Therapeutics
Via Business Wire
Alentis Therapeutics Appoints Dr. Andrea Pellacani as Chief Medical Officer
From Alentis Therapeutics
Via Business Wire
Alentis Therapeutics Starts First-in-Human Clinical Trial for the Treatment of Liver and Kidney Fibrosis
From Alentis Therapeutics
Via Business Wire
Alentis Therapeutics Announces Appointments of Luca Santarelli to the Board of Directors and Rafaèle Tordjman as Chairperson
From Alentis Therapeutics
Via Business Wire
Alentis Therapeutics Raises USD 67 Million in Series B Financing
From Alentis Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story